ATIM-40. HIGH RATE OF OBJECTIVE ANTI-TUMOR RESPONSE IN 9 PATIENTS WITH GLIOBLASTOMA AFTER VIRO-IMMUNOTHERAPY WITH ONCOLYTIC PARVOVIRUS H-1 IN COMBINATION WITH BEVACICUMAB AND PD-1 CHECKPOINT BLOCKADE

類似資料

• ATNT-07 FAVORABLE RESPONSE OF PATIENTS WITH GLIOBLASTOMA AT SECOND OR THIRD RECURRENCE TO REPEATED INJECTION OF ONCOLYTIC PARVOVIRUS H-1 IN COMBINATION WITH BEVACICUMAB
  著者:: Geletneky, Karsten, 等
  出版事項: (2015)
• Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade
  著者:: Antonio Marchini, 等
  出版事項: (2016-01-01)
• Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade
  著者:: Marchini, Antonio, 等
  出版事項: (2016)
• Immunotherapeutic Potential of Oncolytic H-1 Parvovirus: Hints of Glioblastoma Microenvironment Conversion towards Immunogenicity
  著者:: Angelova, Assia L., 等
  出版事項: (2017)
• Tumor Selectivity of Oncolytic Parvoviruses: From in vitro and Animal Models to Cancer Patients
  著者:: Angelova, Assia L., 等
  出版事項: (2015)